Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging our deep domain expertise, we have built a comprehensive ophthalmic drug pipeline of 25 candidates that covers most major ocular indications affecting the front and the back of the eye , through either in-house development or in-licensing. We have also established an advanced ophthalmic manufacturing facility and are assembling an experienced marketing team in anticipation of near-term product launch. Our goal is to become a leader in China and the neighboring ASEAN marketplace.

We are led by an international management team with decades of industry experience and a track record of research and development, clinical operations, manufacturing, regulatory communications, business development and commercialization of ophthalmic therapies.

We have built an ophthalmic drug pipeline comprising 13 innovative drugs and 12 generic drugs as classified under NMPA drug registration regulations. Our innovative pipeline includes 8 drug candidates which have the potential to be market-leading products in China if approved. Our generic pipeline includes 6 potential first-to-market generics in China, which we believe will bring us near-term cash flows and significant first-mover advantages in commercial-scale manufacturing and marketing. According to CIC, we have one of the most comprehensive ophthalmic drug pipelines in China.

In designing our pipeline, we have initially placed strategic emphasis on five major ophthalmic indications in China in terms of market potential, including dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DME, myopia and glaucoma. Through this pipeline strategy, we aim to become the essential one-stop solution.

We have developed internal capabilities in key aspects of ophthalmic drug development. Our specialized in-house research, development, clinical and regulatory capabilities have enabled us to concurrently advance multiple innovative and generic drug candidates through the preclinical and clinical phases. We have a solid track record in business development, having in-licensed a number of drug candidates across major indications with high growth potential from international partners. Setting us apart from competitors in China, we have established a commercial-scale advanced manufacturing facility, which is designed and built for ophthalmic drugs in compliance with cGMP requirements of China, the United States and the European Union. We are also assembling a commercial team with extensive experience covering various nationwide sales channels and ophthalmologists in China. We believe these established capabilities will help us bring innovative and comprehensive ophthalmic therapies to market, and become the partner of choice of multinational pharmaceutical companies.